Literature DB >> 11454101

Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis.

G Shankar1, D A Cohen.   

Abstract

Pulmonary complications and graft-vs.-host disease (GVHD) remain severe threats to survival after bone marrow transplantation (BMT). Idiopathic pneumonia syndrome (IPS) accounts for nearly 50% of all the cases of interstitial pneumonitis after BMT. IPS is characterized by an early inflammatory phase followed by chronic inflammation and fibrosis of lung tissue; however, the immunopathogenesis of this disease is not yet clearly understood. This biphasic syndrome has been reported to be associated with pre-transplant radiation conditioning in some studies while others have suggested that GVHD or autoimmune phenomena may be responsible for its development. The early post-BMT phase is characterized by the presence of inflammatory cytokines whose net effect is to promote lymphocyte influx into lungs with minimal fibrosis, that leads to an acute form of graft-vs.-host reaction-mediated pulmonary tissue damage. Gradual changes over time in leucocyte influx and activation lead to dysregulated wound repair mechanisms resulting from the shift in the balance of cytokines that promote fibrosis. Using data from new animal models of IPS and information from studies of human IPS, we hypothesize that cytokine-modulated immunological mechanisms which occur during the acute and chronic phases after bone marrow transplantation lead to the development of the progressive, inflammatory, and fibrotic lung disease typical of idiopathic pneumonia syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454101      PMCID: PMC2517701          DOI: 10.1111/j.1365-2613.2001.iep0082-0101-x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  128 in total

1.  NHLBI Workshop summary. Current concepts in idiopathic pulmonary fibrosis: a road map for the future.

Authors:  R M Cherniack; R G Crystal; A R Kalica
Journal:  Am Rev Respir Dis       Date:  1991-03

Review 2.  Pulmonary considerations of organ transplantation. Part 2.

Authors:  N A Ettinger; E P Trulock
Journal:  Am Rev Respir Dis       Date:  1991-07

3.  Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.

Authors:  R L Truitt; A A Atasoylu
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

4.  Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts.

Authors:  A S Narayanan; J Whithey; A Souza; G Raghu
Journal:  Chest       Date:  1992-05       Impact factor: 9.410

Review 5.  Graft-versus-host disease.

Authors:  J L Ferrara; H J Deeg
Journal:  N Engl J Med       Date:  1991-03-07       Impact factor: 91.245

Review 6.  Lymphocyte recruitment to the lung.

Authors:  J S Berman; D J Beer; A C Theodore; H Kornfeld; J Bernardo; D M Center
Journal:  Am Rev Respir Dis       Date:  1990-07

Review 7.  Pathobiology of pulmonary fibrosis.

Authors:  E Crouch
Journal:  Am J Physiol       Date:  1990-10

8.  Hyper IgE in stimulatory graft-versus-host disease: role of interleukin-4.

Authors:  J M Doutrelepont; M Moser; O Leo; D Abramowicz; M L Vanderhaegen; J Urbain; M Goldman
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

9.  Pneumonitis in bone marrow transplant recipients results from a local immune response.

Authors:  H J Milburn; R M Du Bois; H G Prentice; L W Poulter
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

10.  Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease.

Authors:  F P Nestel; K S Price; T A Seemayer; W S Lapp
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  11 in total

1.  Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.

Authors:  J W Chien; M Sakai; T A Gooley; H G Schoch; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2009-06-29       Impact factor: 5.483

Review 2.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

3.  Loss of CCR2 signaling alters leukocyte recruitment and exacerbates γ-herpesvirus-induced pneumonitis and fibrosis following bone marrow transplantation.

Authors:  Stephen J Gurczynski; Megan C Procario; David N O'Dwyer; Carol A Wilke; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-22       Impact factor: 5.464

4.  High-resolution computed tomography features of pulmonary chronic graft-versus-host disease following hematopoietic stem cell transplantation: histopathological correlation.

Authors:  Noriyo Yanagawa; Fumikazu Sakai; Noriko Kamata; Tsunekazu Hishima; Tamiko Takemura; Kazuteru Ohashi
Journal:  Jpn J Radiol       Date:  2011-02-27       Impact factor: 2.374

5.  Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.

Authors:  Bipin N Savani; Aldemar Montero; Ramaprasad Srinivasan; Anurag Singh; Aarthi Shenoy; Stephan Mielke; Katayoun Rezvani; Shervin Karimpour; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

6.  A new murine model for bronchiolitis obliterans post-bone marrow transplant.

Authors:  Angela Panoskaltsis-Mortari; Kevin V Tram; Andrew P Price; Christine H Wendt; Bruce R Blazar
Journal:  Am J Respir Crit Care Med       Date:  2007-06-15       Impact factor: 21.405

7.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

8.  Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Authors:  Sandra Miklos; Gunnar Mueller; Yayi Chang; Abdellatif Bouazzaoui; Elena Spacenko; Thomas E O Schubert; David J Grainger; Ernst Holler; Reinhard Andreesen; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2009-03-14       Impact factor: 2.490

9.  Mesenchymal stem cells alleviate idiopathic pneumonia syndrome by modulating T cell function through CCR2-CCL2 axis.

Authors:  Min Cao; Huihui Liu; Yujun Dong; Wei Liu; Zhengyu Yu; Qingya Wang; Qingyun Wang; Zeying Liang; Yuan Li; Hanyun Ren
Journal:  Stem Cell Res Ther       Date:  2021-07-02       Impact factor: 6.832

10.  Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.

Authors:  Sun Bean Kim; Sung-Yeon Cho; Dong-Gun Lee; Jae-Ki Choi; Hyo-Jin Lee; Si-Hyun Kim; Sun Hee Park; Su-Mi Choi; Jung-Hyun Choi; Jin-Hong Yoo; Jong-Wook Lee
Journal:  Med Mycol       Date:  2017-04-01       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.